Metagenomi Therapeutics (MGX)
Develops genetic medicines from microbial genome-editing systems.
Something off on this page? Send us feedback.
Genetic medicines are developed from editing systems discovered in microbial genomes. A modular platform supports a wholly owned hemophilia A program, later-stage preclinical programs, and selected cardiometabolic work with Ionis.
Develops in-vivo genetic medicines from editing systems discovered in microbial genomes. Its modular platform includes programmable nucleases, base editors, and RNA- and DNA-mediated integration systems.
The wholly owned pipeline is centered on MGX-001 for hemophilia A, alongside later-stage preclinical programs. The company also advances selected cardiometabolic programs with Ionis through its site-specific integration, deletion, and correction capabilities.
Its development model combines discovery and engineering with collaborations. It retains full global rights to specified editing technologies. Progress depends on financing, clinical and regulatory advancement, and its ability to develop programs and collaborations.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $120.7M · Total debt $37.7M · Total assets $173.7M · Shareholders' equity $112.6M
- Revenue
- −$257.0K
- Operating income
- −$28.8M
- Net income
- −$27.5M
No dividends on record.
| Institutions47 holders · as of Mar 31, 2026 | 17.11% | 6.46M shares | |
| Insiders5 holders · as of Jun 10, 2026 | 9.29% | 3.51M shares | |
| Otherremainder | 73.60% | 27.80M shares |
37.78M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Brian C. ThomasInsiderdirector | 6.65% | 2.51M | Form 4filed Dec 8, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 2.80% | 1.06M | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 2.09% | 787,900 | 13Fas of Mar 31, 2026 |
Jian IrishInsiderdirector, officer: See Remarks | 1.47% | 556,016 | Form 4filed Jun 10, 2026 ↗ |
Catalio Capital Management, LPInstitution | 1.40% | 528,993 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 5, 2026 | Matthew Wein | officer: See Remarks | −558 | $1.30 |
| Jun 5, 2026 | Jian Irish | director, officer: See Remarks | −3,737 | $1.30 |
| Jun 5, 2026 | Pamela Wapnick | officer: Chief Financial Officer | −2,884 | $1.30 |
| Mar 5, 2026 | Jian Irish | director, officer: Chief Executive Officer | −1,607 | $1.60 |
| Mar 5, 2026 | Matthew Wein | officer: See Remarks | −482 | $1.60 |
- CRISPR Therapeutics
In-vivo CRISPR editing across liver, cardiometabolic, and blood diseases
- Intellia Therapeutics
Clinical in-vivo CRISPR editing for liver-produced disease proteins
- Beam Therapeutics
Base-editing platform for in-vivo liver and hematology medicines
- Prime Medicine
Prime-editing platform for one-time in-vivo genetic therapies
- Precision BioSciences
ARCUS nuclease platform with clinical in-vivo editing programs
- Editas Medicine
In-vivo gene editing for cardiometabolic disease targets
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Metagenomi Therapeutics | $1.17 | 0.00% | $43.7M | — | — | 3.2 | −103.0% |
| CRISPR Therapeutics | $56.80 | −0.17% | $5.49B | — | — | 409.9 | +1,041.4% |
| Intellia Therapeutics | $12.90 | +1.14% | $1.78B | — | — | 30.0 | −46.2% |
| Beam Therapeutics | $29.57 | +0.89% | $3.01B | — | — | 19.3 | −94.2% |
| Prime Medicine | $3.67 | −0.41% | $662.9M | — | — | 162.7 | +3.5% |
| Precision BioSciences | $7.60 | +1.88% | $95.6M | — | — | 2.1 | −100.0% |
| Editas Medicine | $3.14 | +2.41% | $472.7M | — | — | 10.1 | +232.3% |
| Median | — | — | 24.6 | −21.4% |